VYNE Reports Narrower Loss in Fiscal Q2
VYNE Therapeutics (NASDAQ:VYNE), a biotechnology company developing new therapies for inflammatory and autoimmune diseases, reported second quarter 2025 results on August 14, 2025. The most important news was a significant improvement in GAAP net loss per share compared to Q2 2024, with GAAP earnings per share at $(0.13) compared to the consensus GAAP estimate of $(0.22). GAAP revenue came in at $0.1 million, below the $0.15 million analysts expected (GAAP), and down from the prior year’s $0.2 million (GAAP). The period reflected ongoing cost reductions and expense management that helped narrow losses, but pipeline challenges remained after its lead product, repibresib gel, failed to meet objectives in a key clinical trial.
Source: Analyst estimates for the quarter provided by FactSet.
The company is a clinical-stage biopharmaceutical firm focused on developing medicines for chronic inflammatory and immunological diseases. Its platform centers on BET (bromodomain and extraterminal domain) inhibitors—molecules that regulate genes linked to inflammation and immune response. These therapies are intended to treat conditions with few effective options.
Source Fool.com
